Herpes simplex viruses (HSV)1 and HSV2 cause a variety of human diseases, including encephalitis, keratitis, neonatal disease, and mucocutaneous and skin diseases such as herpes labialis, genital herpes, and herpetic whitlow. HSV1 gB, which is a class III fusion glycoprotein, is a major target of antibodymediated immunity (21). It plays an essential role in the entry of the virus into a host cell, together with other HSV1 envelope glycoproteins, including gD and a complex of gH and gL (gH/gL). - Antikörper
Tag:
Human IgG1 | Human Kappa
Puffer:
PBS, pH7.4
Reinheit:
0.95
Formulierung:
Powder
Target-Kategorie:
gB
Immobilized HSV-1 (strain KOS) post-gB Protein, His Tag (Cat. No. POB-V52H3) at 1 µg/mL (100 µL/well) can bind Monoclonal Anti-HSV-1 (strain KOS) gB Antibody, Human IgG1 (1A2) (Cat. No. HSB-MY2113) with a linear range of 0.1-2 ng/mL (QC tested).
Immobilized HSV-2 (strain 333) Glycoprotein B (gB), His Tag (Cat. No. GLB-H52H3) at 1 µg/mL (100 µL/well) can bind Monoclonal Anti-HSV-1 (strain KOS) gB Antibody, Human IgG1 (1A2) (Cat. No. HSB-MY2113) with a linear range of 0.06-2 ng/mL (Routinely tested).
Monoclonal Anti-HSV-1 (strain KOS) gB Antibody, Human IgG1 (1A2) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 0.95.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
